Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Motor Neuron Progenitor”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Early research (Phase 1)Looking for participantsNCT07118319
What this trial is testing

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

Who this might be right for
Amyotrophic Lateral Sclerosis (ALS)
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. 12
Early research (Phase 1)Active Not RecruitingNCT05306457
What this trial is testing

CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS

Who this might be right for
Amyotrophic Lateral Sclerosis
Cedars-Sinai Medical Center 16
Early research (Phase 1)Study completedNCT02943850
What this trial is testing

CNS10-NPC-GDNF for the Treatment of ALS

Who this might be right for
Amyotrophic Lateral Sclerosis
Cedars-Sinai Medical Center 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06974968
What this trial is testing

Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial

Who this might be right for
Spinal Cord InjurySafetyEfficacy+5 more
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. 60
Early research (Phase 1)Looking for participantsNCT06976229
What this trial is testing

Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

Who this might be right for
Spinal Cord InjurySafetyClinical Trials+4 more
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. 12
Testing effectiveness (Phase 2)UnknownNCT02478450
What this trial is testing

Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)

Who this might be right for
Amyotrophic Lateral Sclerosis
Q Therapeutics, Inc. 30